PMID- 26951082
OWN - NLM
STAT- MEDLINE
DCOM- 20170206
LR  - 20220408
IS  - 1472-4146 (Electronic)
IS  - 0021-9746 (Linking)
VI  - 69
IP  - 8
DP  - 2016 Aug
TI  - A systematic review and meta-analysis of immunohistochemical biomarkers that 
      differentiate chromophobe renal cell carcinoma from renal oncocytoma.
PG  - 661-71
LID - 10.1136/jclinpath-2015-203585 [doi]
AB  - BACKGROUND: Numerous immunohistochemical (IHC) biomarkers have been employed to 
      aid in the difficult differentiation between chromophobe renal cell carcinoma 
      (chRCC) and renal oncocytoma (RO). A systematic review and meta-analysis of the 
      published literature was carried out to summarise and analyse the evidence for 
      discriminatory IHC biomarkers to differentiate the two entities. METHODS: PubMed 
      database was used to identify relevant literature. Primary end point was 
      comparison of positive immunostaining of the biomarkers in chRCC and RO, with 
      extracted data used to calculate OR and 95% CI and statistical I(2) test of 
      heterogeneity for multiple studies. RESULTS: One hundred and nine manuscripts 
      were available for review. Data extracted were subjected to quantitative 
      meta-analysis. Ten most effective biomarkers (OR of chRCC/RO and CI) are: amylase 
      alpha1A (n=129, OR=0.001, 95% CI 0.0001 to 0.019); Wnt-5a (n=38, OR=0.0076, 95% CI 
      0.0004 to 0.015); FXYD2 (n=57, OR=130, 95% CI 14.2 to 1192.3); ankyrin-repeated 
      protein with a proline-rich region (ARPP) (n=25, OR=0.0054, 95% CI 0.0002 to 
      0.12); cluster of differentiation 63 (CD63) (n=62, diffuse (chRCC) vs 
      apical/polar (RO) stain pattern); transforming growth factor beta 1 (TGFbeta1) (n=34, 
      membranous (chRCC) vs cytoplasmic (RO)); cytokeratin 7 (CK7) (11 studies, n=448, 
      pooled OR=44.22, 95% CI 22.52 to 86.64, I(2)=15%); S100A1 (4 studies, n=124, 
      pooled OR=0.01, 95% CI 0 to 0.03, I(2)=0%); caveolin-1 (2 studies, n=102, pooled 
      OR=32.95, 95% CI 3.67 to 296.1, I(2)=70%) and claudin-7 (3 studies, n=89, pooled 
      OR=24.7, 95% CI 6.28 to 97.1, I(2)=0%). CONCLUSIONS: We recommend a panel of IHC 
      biomarkers of amylase alpha1A, Wnt-5a, FXYD2, ARPP, CD63, TGFbeta1, CK7, S100A1, 
      caveolin-1 and claudin-7 to aid in the differentiation of chRCC and RO.
CI  - Published by the BMJ Publishing Group Limited. For permission to use (where not 
      already granted under a licence) please go to 
      http://www.bmj.com/company/products-services/rights-and-licensing/
FAU - Ng, Keng Lim
AU  - Ng KL
AD  - Department of Urology, Princess Alexandra Hospital, Brisbane, Australia Centre 
      for Kidney Disease Research, School of Medicine, Translational Research 
      Institute, University of Queensland, Brisbane, Australia Department of Surgery, 
      University Malaya, Kuala Lumpur, Malaysia.
FAU - Morais, Christudas
AU  - Morais C
AD  - Centre for Kidney Disease Research, School of Medicine, Translational Research 
      Institute, University of Queensland, Brisbane, Australia.
FAU - Bernard, Anne
AU  - Bernard A
AD  - QFAB Bioinformatics, Institute for Molecular Bioscience, University of 
      Queensland, Brisbane, Australia.
FAU - Saunders, Nicholas
AU  - Saunders N
AD  - University of Queensland Diamantina Institute, University of Queensland, 
      Brisbane, Australia.
FAU - Samaratunga, Hemamali
AU  - Samaratunga H
AD  - Aquesta Pathology, Brisbane, Australia.
FAU - Gobe, Glenda
AU  - Gobe G
AD  - Centre for Kidney Disease Research, School of Medicine, Translational Research 
      Institute, University of Queensland, Brisbane, Australia.
FAU - Wood, Simon
AU  - Wood S
AD  - Department of Urology, Princess Alexandra Hospital, Brisbane, Australia.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20160307
PL  - England
TA  - J Clin Pathol
JT  - Journal of clinical pathology
JID - 0376601
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adenoma, Oxyphilic/*diagnosis/metabolism/pathology
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Renal Cell/*diagnosis/metabolism/pathology
MH  - Diagnosis, Differential
MH  - Humans
MH  - Kidney Neoplasms/*diagnosis/metabolism/pathology
OTO - NOTNLM
OT  - CARCINOMA
OT  - DIFFERENTIATION
OT  - IMMUNOHISTOCHEMISTRY
OT  - RENAL CANCER
OT  - TUMOUR MARKERS
EDAT- 2016/03/10 06:00
MHDA- 2017/02/07 06:00
CRDT- 2016/03/09 06:00
PHST- 2015/12/21 00:00 [received]
PHST- 2016/02/15 00:00 [accepted]
PHST- 2016/03/09 06:00 [entrez]
PHST- 2016/03/10 06:00 [pubmed]
PHST- 2017/02/07 06:00 [medline]
AID - jclinpath-2015-203585 [pii]
AID - 10.1136/jclinpath-2015-203585 [doi]
PST - ppublish
SO  - J Clin Pathol. 2016 Aug;69(8):661-71. doi: 10.1136/jclinpath-2015-203585. Epub 
      2016 Mar 7.